What’s Clovis Oncology’s Return Potential?

Company overview

Clovis Oncology (CLVS) is a biopharmaceutical company with a focus on acquiring, developing, and commercializing anti-cancer agents. Clovis’s Rubraca (rucaparib), launched in the United States in December 2016, is approved for treating adult patients with deleterious BRCA[1.breast cancer susceptibility gene]-mutation epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received two or more chemotherapies.

What’s Clovis Oncology’s Return Potential?

Analysts’ recommendations

Of the nine analysts covering Clovis Oncology, seven have recommended “buy” or a higher rating, while two have recommended “hold.” Clovis’s target price of $79.57 implies a 67.4% upside based on the stock’s May 24 closing price of $47.52.

Peer ratings

  • Of the 25 analysts covering Regeneron Pharmaceuticals (REGN), eight have recommended “buy” or a higher rating, 16 have recommended “hold,” and one has recommended “sell.” Their mean rating for the stock is 2.6, and their target price is $374.16.
  • Of the 13 analysts covering Ionis Pharmaceuticals (IONS), four have recommended “buy” or a higher rating, seven have recommended “hold,” and two have recommended “sell” or a lower rating. Their mean rating for the stock is 2.9, and their target price is $59.91.
  • Of the 23 analysts covering Amgen (AMGN), 11 have recommended “buy” or a higher rating, while 12 have recommended “hold.” Their mean rating for the stock is 2.3, and their target price is $195.35.

In the next part of this series, we’ll look at Clovis Oncology’s pipeline.